MOCI On a Path to Disrupt Global Media Production and Distribution

As the third quarter winds down, market participants are beginning to see a move toward a diffusion of capital by larger fund managers. Higher nominal growth in the global economy is sparking a rotation trade out of mega-cap technology stocks like Facebook (FB), Google (GOOGL), and Amazon (AMZN). And rumors of a tax reform bill hitting the wires has fueled a rush of those funds into domestic, high-beta stocks.

That means: small caps and micro-caps are on the move again.

The river of money coming into these market segments will be looking for two things: a good story and an undervalued position relative to a big end market. As far as we can see, MOCI is as attractive as anything out there from that perspective. However, this company is more than just another pretty face value setup: these guys are up to something that could be a unique and valuable innovation a market segment with virtually no pure-play competition.

The game is the coordination and development of a new model of market-based funding mechanisms supporting independent cinematic media that explicitly targets underserved emerging markets. It’s fascinating, and it might be hugely lucrative as well.

Quick Facts:

• MOCICEO Ross Cooper is one of the most experienced guys in the industry, with three decades in the game.
• MOCIalready owns a successful Chinese film fund and is looking to expand its operational reach and investments in emerging markets worldwide.
• MOCIhas begun to crusade for a new process to manage and view mobile video, with an innovative exchange model to network together financing from .
• MOCIis an emerging leader in the nearly $80B mobile app space.
• MOCIis coming off an RSI trough under 45, pointing to a massively oversold stock now heading back the other way.
• MOCIjust recorded a MACD Bullish reversal, suggesting a technical change in trend.
• MOCIis knocking on a potential technical breakout that could occur on a surge above the 200-day simple moving average at $0.95. The stock recently broke out above its 50-day SMA earlier this year, and has held those gains.

Understanding the Basic Story

Modern Cinema Group Inc. (OTCMKTS:MOCI)is gearing up, as far as we can see through our research, to disrupt the business of film making. This is a new kind of Hollywood studio. The emphasis is on creating a new model for how movies and television shows are financed as the modern content-sphere becomes an increasingly global phenomenon.

If you set out to make a new film, you may need to go affiliate with a major production house and they will work with you to pitch to investors and fund the production if the project makes business sense.

That’s the way it is currently done, and has been done for a long time.

MOCI is looking to change all of that. That model doesn’t work if you have a project that could really work in the emerging world. The fundraising step is where the operation breaks down. However, MOCI is working on a model that borrows from the mechanisms inherent in the functioning of futures exchanges to distribute the weight of the financing process among self-interested and unconnected speculators.

If the model gets traction, it could truly revolutionize not only how films and TV series are financed, but also the range of projects that can be seen as economically viable in the first place. This last point is critical to fostering a burgeoning media consumer culture in market territories such as Asia, Europe, Africa and South America. But, whoever solves that puzzle could potentially capture and have direct connection to over 50% of the world's population. So this is Big Game stuff.

That brings us to another point of strength: The company’s CEO is Ross Cooper, a man with 30 years of experience as a successful entrepreneur and corporate officer. According to the company’s materials, Mr. Cooper is also an accomplished inventor with numerous patents to his name.

From what we can see, Cooper has been an innovator throughout his career and continues to find avenues that provide an edge. He has a few exits already as an entrepreneur and managed to entrench himself in the fabric of Hollywood as the Executive Producer for movie, television and music projects.

Mr. Cooper has been responsible for the creation and operation of many companies in the areas of Media & Entertainment, Education, Psychometrics and Health Sciences.  Mr. Cooper is currently negotiating the rights to his original story named “Wingman”.

Now, he leads this new effort to exploit the virgin territory of emerging market dynamic media content financing and distribution. According to company materials, MOCI has numerous divisions that provide novel and timely solutions with the ultimate goal of building a worldwide dominant motion picture network. Right now, Modern Cinema Group provides libraries of movies, television and game content to large population groups by way of its distribution partners (primarily mobile carriers).

During the summer of 2014, Modern Cinema opened a film (and media) financing fund within the Free-Trade located in Shanghai China before these types of funds were closed to foreign entities.

Since China is now the largest market for filmed entertainment, and media investments in China are highly attractive to the numerous funds; Modern Cinema Group is well positioned to either finance or co-finance productions along with Chinese entities (both private and corporate). Modern Cinema plans to begin Chinese Co-Productions in early 2018.

One of the company’s primary insights is a focus on “pre-positioning” media content, where users are able to gain on-demand access to content actually stored locally on the device. This circumnavigates one of the primary hurdles to consumer experience of media where infrastructural resources are second- or third-tier.

With this in mind, one can imagine that MOCI execs are targeting the 2018 World Cup as a major breakout point for the business: nothing is more core for emerging market media engagement than the World Cup. And this is exactly when mobile carriers will need to increase efficiencies as these games will introduce unprecedented demands on mobile networks in Latin America, Europe and Asia. Modern Cinema Group and its partners are working to secure opportunities for the World Cup now.
 

A Brave New World

The move to focus on emerging markets is itself enormously compelling precisely because the niche offers a mouth-watering combination of low-competition and high potential growth over time. The only hurdle is the technological barrier to entry: the reason why competition is low is because the economics normally don’t favor targeting media towards emerging markets given that costs of production and distribution may be higher and revenues from things like advertising are normally going to be quite a bit lower. So, the ROI simply isn’t there.

That is true unless you start with a new model for both financing projects and distributing media. That appears to be exactly where the MOCI story is going. With a diversified funding draw model and an ability to drive high-quality locally-relevant media content to consumers operating on older (3G and 4G) mobile networks with major delays or buffering obstacles is the holy grail. And it would appear that Cooper has his team on tract to make a run at this outcome through Multicasting using MBMS. Newer LTE networks will use eMBMS or LTE Broadcasting.

As the company’s materials explain, this allows both older 3G/4G and newer LTE networks to potentially send our content to millions of user devices simultaneously.  The content titles will be stored on user’s devices to be played at a later time (On-Demand) — the Pre-Positioning methodology we covered earlier.

According to the company’s website, MOCI Media is already in contract negotiations with mobile carriers located around the world.

Technical Analysis

As it stands, the stock has been increasingly showing signs of a being in a new and burgeoning bullish trend: we saw a clear bullish breakout above its 50-day simple moving average in June on a bullish inflection in the MACD indicator.

Those gains have been preserved, and the stock is now clearly knocking on the door of a similar breakout above its 200-day SMA as well. That could push shares above the key psychological marker at the $1/share level.

All of this has happened ahead of a planned surge in investor relations noted by management as a next step, suggesting that we are sitting in front of a positive technical feedback loop with major implications.

About MOCI

MOCI (Modern Cinema Group Inc.) is a new Hollywood studio “disrupting the way movies and television series are financed in the new Golden Age of Content Everywhere.”

Based in Beverly Hills, founded in San Diego, the company has a decidedly technological spin on how to finance movies by allowing the world's largest Multichannel Video Program Distributors (primarily Cable and Satellite Operators) to compete with on-line services by offering their own branded Hollywood movies and television series. The production budgets for movies being between $40 million and $100 million. Budgets for television series in the range of $100 million per season. Financing partnerships currently in place with numerous Chinese Film funds.

Sincerely,

AST

Disclaimer:
We have received five thousand dollars via a bank wire for the awareness of MOCI.
All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.

We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.

Any type of reproduction, copying or distribution of the material in this blog is prohibited without a written consent from the site owner.

Following our enormous win the junior gold mining space earlier this month, we are now ready to turn our attention to another market segment that offers the potential for home runs and grand slams on a regular basis: biotechnology.

Now lets research OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP). And, fortunately, it’s not a difficult study: there’s a ton to like here right now, particularly following the company’s most recent announcement detailing its success in its Phase Ia trial for its lead pipeline asset, ProscaVax, which is now heading into a Phase II study with momentum and promise, and toward the $7B prostate cancer market.

But OBMP is not as simple as the ProscaVax story. In recent months, under the leadership of its …., the company has diversified widely with the goal of funding future operations and R&D through actual revenues rather than hopes, promises, and dilution, which is the more common path for early-stage biopharma plays. That’s our focus today: why this company is different.

Quick Facts:

• OBMP has a small trading float of just 9.8M shares, which suggests the stock could launch higher on any additional influx of interest.
• OBMP has a lead drug candidate heading into the possible commencement of critical Phase 2 trials in the $7B prostate cancer space, with phase one now well sorted out.
• OBMP acquired the rights to six Aagaard Propolis products for the Mexican markets from the Company’s German partner roha Arzneimittel GmbH over the Summer. OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.
• OBMP also recently submitted an application to COFEPRIS seeking approval to commercialize an anti-rabies drug licensed from a NASDAQ-listed biopharmaceutical company.
• OBMP is working to complete licensing negotiations with the manufacturer of a key treatment with the goal of adding the new AAT therapy product to the Company’s portfolio for the Mexican market.
• OBMP management recently noted that the company had a total of 48 drugs/drug candidates that “are already under our control for specific markets or are the subject of negotiations.”
• OBMP is one of the most diversified biopharma microcaps on the OTC today, with an enormous array of revenue paths set to hit over coming quarters.

Understanding the Basic Story

OncBioMune has too often been lumped into the one-horse prostate cancer lotto as a shorthand way to understand the company. And that has misled longer-term shareholders into giving up on the story, which is perhaps the most compelling reason for new investors to take notice and give this stock a fresh appraisal. The critical factor in understanding exactly why that one-horse prostate cancer lotto story is wrong is the company’s process of intense diversification in its top-line potential over the past 6 months. In that time, we have seen one announcement after another that all focus on the same narrative: marketing and distribution rights to therapies that have commercial viability now.

The story really started with the acquisition of Vitel Laboratorios, S.A. de C.V, which got the
ball rolling for sales in Mexico of the Company’s licensed products, Bekunis for constipation
and Cirkused for stress. They both exceeded projections during the first six months on the
market and represented two commercially viable horses in the stable.

Sales from September 16, 2016 to February 16, 2017 were approximately $330K, exceeding
projections for $125K initially forecast for the first six months at product launch during the third
quarter last year. The Company anticipates that sales efforts will continue to accelerate and
anticipates combined sales in the range of US$750,000 to $850K for the products in 2017.

But that was just the beginning.

Just after the Vitel move, OBMP execs pulled off another similar move, announcing the signing of a licensing agreement between the Company and PROCAPS S.A.S. granting OncBioMune rights to tretinoin, also known as all-trans retinoic acid (ATRA), an oral drug for the treatment of Acute Promyelocytic Leukemia (APL), throughout Mexico, Central America and Latin America.

That was followed by the company’s announcement of an exclusive distribution and licensing agreement between OncBioMune and AqVida GmbH, a Germany-based FDF manufacturer specializing in the development, registration, manufacturing and distribution of generic pharmaceutical products, with an emphasis on the field of cancer therapy from their state-of-the-art facility in Dassow, Germany.

OncBioMune and AqVida are currently conducting negotiations regarding expanding the exclusive licensing agreement to cover commercialization in the Mexican markets the complete AqVida portfolio of medicines, including several used for treating the most common types of cancer.

Rather remarkably, the blitz toward commerce and revenues did not end there.

The company recently announced that it has formally acquired the rights to six Aagaard Propolis products for the Mexican markets from the Company’s German partner roha Arzneimittel GmbH. OncBioMune has begun the process to market the products across Mexico, with expectations for an official launch during the fourth quarter of 2017.

In this string of strategic moves, one might easily have overlooked yet another move tucked into the middle of Summer, when the company announced that it is now working to complete licensing negotiations with the manufacturer of a key treatment with the goal of adding the new AAT therapy product to the Company’s portfolio for the Mexican market.

Most recently, in an interesting move, the company has also recently submitted an application to COFEPRIS seeking approval to commercialize an anti-rabies drug licensed from a NASDAQ-listed biopharmaceutical company.

The Revenue Train

Hence, this is far, far more than just an early stage R&D play in the prostate cancer space. This is quite possibly the preeminent rising biopharma play in the Mexican and Latin American markets, with commercially viable revenue streams taking root in markets as diverse as Stress, Constipation, Rabies, AAT, Cancer, and Leukemia.

The moves are already starting to pay off. The company announced sequential top-line Q2 growth of 935%. That type of number should send a flare up to momentum investors if the stock starts to establish some newfound momentum on the chart.

We are coming into the end of Q3, and folks are sure to start to pricing in another major jump in sales. But the real remarkable point might come into year-end, when several of the company’s newest horses start to leave the stable and join the race, such as the six new products it will begin commercializing in Mexico in Q4 as part of its roha partnership deal.

However, perhaps the most interesting story is the mysterious AAT deficiency opportunity recently alluded to in company communications. Management is being a little cagey about the details for competitive reasons, but they are not being coy about its market potential.

“This is absolutely a blue ocean opportunity for us that could generate tens of millions of dollars in high-margin revenue by helping just a small portion of patients with AAT deficiency in Mexico. The first patient’s private insurance has already agreed to reimbursement, a positive sign for us moving forward,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “Patients with AAT deficiency need to know that they have the disorder as soon as possible, information that could potentially lower the risk of developing life-threatening diseases by early intervention. We are optimistic that we will successfully negotiate the licensing agreement and fill this area of unmet medical need in Mexico.”

AAT deficiency is a lifelong condition requiring weekly injections, with the cost of some popular insurance-covered therapies in excess of $100,000 annually. That’s where the “tens of millions in high-margin revenue” notion comes from.Any way you slice the OBMP story right now, you get further and further away from the typical “one-horse, pre-revenue biotech betting it all on a long-shot.” This is strategically diverse commercial-stage organization with 48 horses in the stable and a radical top-line revenue growth acceleration that has already begun.

ProscaVax
 

That said, the biggest horse in the stable is still its prostate cancer ticket, ProscaVax.

The drug recently completed a Phase 1-a study with strong results. The study enrolled 20 biochemically progressing prostate cancer patients, four of which dropped out due to disease progression (3 with increasing PSA, 1 radiological).

Perhaps even more interestingly, the study further evaluated secondary objectives that could suggest efficacy for ProscaVax having a meaningful benefit in treating late-stage prostate cancer. According to the company, “At a median follow-up of 31 months post-final vaccination, 9 of the 14 evaluable patients (64.3%) who received all six vaccinations had increased PSA doubling time, suggesting ProscaVax was slowing tumor growth. 12 of 15 patients (80.0%) completing the protocol had an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay.”

That is basically the ideal outcome for a Phase 1 study: no toxicity, but indications of a therapeutic benefit. From here, we will likely now see the company release full details of the plan going forward, including the outline of its upcoming Phase 2 research on the drug.

As noted above, the prostate cancer market is massive, with over $7B in total sales on the line. If the market begins to take ProscaVax seriously – as a real contender in this space – then we could be looking at a massive repricing of OBMP shares. The successful closing of its Phase 1 study puts that on the table going forward.

About OBMP

OBMP (OncBioMune Pharmaceuticals Inc.) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products.The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. The company also has a portfolio of targeted therapies for international marketing and is headquartered in Baton Rouge, Louisiana.

Disclaimer:
We have received five thsnd dollars via a bank wire for the awareness of OBMP.
We have previously received five thsnd dlrs via a bank wire for the awareness of OBMP which has since expired.

All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.

We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.

2017's Biotech Alert of the Year Is Here! INOL's Inojex30 is the ONLY FDA Approved Device Of It's Kind in a $9.8 Billion Market! With a Shortage of 300,000 Devices in North America Alone, Demand is Already Exceeding Supply – Making INOL The Biotech Play of the Year!

INOL's revolutionary drug delivery device could transform a $9.8 Billion industry that is expected to hit $20 Billion by 2021.
 

Hi and good evening,

Tonight is pretty special, often is the case in the small markets that we find companies that are in the process of tapping into their potential but INOL is in rarified air. This will not be a long-winded report, tonight is too important for that, instead I'll stay on point with what you need to know before tomorrow morning. In a single paragraph I'll sum up INOL for you.

The amazing INOL story in one paragraph:

INOL's device is FDA Approved; in fact, it is the ONLY FDA approved over-the-counter needle-free injection device on the market today. Last year, in North America alone there was a shortage of 300,000 such needle-free devices. Instead of a traditional syringe with a needle, INOL's device injects medicine under the skin more efficiently and painlessly. It can be used to deliver "shots" for the treatment of Diabetes, Local Anesthesia, Vaccines & Growth Hormones as well as use in Dental, Veterinary and Aesthetic / Beauty practices. This summer INOL engaged investment banking firm Maxim Group LLC, a firm with $2.8 Billion under management, to assist INOL with funding so that INOL can help fill the 300,000 device shortage. As part of INOL's agreement with Maxim, Maxim will help INOL qualify and uplist to NASDAQ Capital Market. INOL's device is also approved by Health Canada (for use in Canada) and the European Medicines Agency (for use in Europe).

Now we can get into the details, but you already know the story… and it's an incredible one! So get INOL on your screen now and be ready tomorrow morning!

INOL has been called, "2017's Top Biotech Pick of the Year". See that very detailed report here:
www.INOLReport.com

This is INOL's device, the Inojex30:

Here is the FDA's website showing you Inojex30's Product code, Device Class, Registration Number, Classification Name and that this is registered to the INOL as the owner:

INOL is anything but normal; don't let it pass you by. This could be a tremendously undervalued ground floor play. Get started on your research now and be ready for tomorrow morning.
 

InoLife Technologies Inc. (INOL) develops and commercializes drug delivery devices, drug delivery technologies and products for the cure and care of our global customers. INOL's flagship product, the Inojex30, is an innovative needle-free technology that delivers a fine stream of medication subcutaneously without using a needle.

INOL's Inojex30 "fine stream of medication" is less than half the radius of a needle and delivers the medicine in a more efficient, uniform manner than traditional needles.

INOL recently engaged the services of investment bank Maxim Group to bring INOL and their technology to the next level.

At the time of INOL/Maxim's agreement, INOL President stated:

"This is a very important milestone for Inolife on our path to graduating to a national stock exchange," said Mr. Michael Wright, President & CEO of Inolife. "Maxim Group is a respected full-service investment banking firm with an impressive track-record of success in helping healthcare companies grow, and we are confident that they are the right corporate finance partner for Inolife."

INOL's biotechnology has a lot going for it right now:

• Been approved by three top regulatory agencies, including the FDA
• Manufactures only FDA approved over-the-counter needle-free injection device
• Expecting to uplist to NASDAQ in 2018 following recent agreement with Maxim Group LLC

Those accomplishments and benchmarks are impressive enough yet what truly places INOL in an enviable position is growing demand inside the market they operate.

• From 2012 to 2016 the injectable market has seen an increase of 43%
• Injectable Drug Delivery Market worth 624.50 Billion USD by 2021
• Currently, 16 Billion injections are received worldwide annually
• Demand exceeds supply in North America, resulting in a shortage last year of 300,000 needle-free devices

As if this wasn't enough, the technology used by INOL is being backed by prominent organizations such as the World Health Organization, Centers for Disease Control and Prevention and various groups including the Bill and Melinda Gates Foundation.

Just what is this technology? Well it's an innovative needle-free technology that delivers a fine stream of medication subcutaneously without using a needle. The injections with the InoLife Inojex are virtually pain-free and do not lead to tissue damage on long term use. The InoLife injector is a reusable device, which utilizes disposable ampoules and other accessories.

We mentioned potential earlier and the opportunities that exist for this technology are vast. INOL lists a full menu of uses for their Inojex needle-free injector and these include:

• Diabetes
• Local Anesthesia
• Dental
• Vaccines & Growth Hormones
• Veterinary
• Aesthetic / Beauty

It's pretty easy to understand why we are excited about INOL. The regulatory approval alone is enough to take notice, as is the market size and expected growth, so too are the many uses of this technology. Now understand that we have all three of these together in one company.

Simply put, INOL should absolutely be on the top of your trading screen tomorrow!

Like I said, tonight's play is pretty rare and pretty special. It's not often you see a company with a technology this advanced and FDA approved on the small markets.

I make no attempt to hide our love for biotech. There are few things in the small markets more beautiful and more exciting than a biotech that catches fire.

When investors find a new biotech that they can get behind it can skyrocket!

INOL could be that next biotech to capture the imagination of the small market and light it up!

Also, today INOL slid all the way down to .15, although the bid and offer has already started to rise back up.

Yesterday INOL closed at .30 and it was trading up over $2 this summer!

Today's slide could have opened a very big door.

Not only does INOL have operations that could place its value well above its current level, it could also see a significant bounce right around the corner.

A return to where it was this morning could translate to a 100% run.

A return to its summer levels could translate to a colossal run of 1,233%.

It's not often that we see situations like this; this play could be epically undervalued!

Now to be clear no one is expecting it to see a return to those summer levels in the short term, but even a fraction could translate to a massive percentage!

Like I said at the start, tonight's play is something quite special.
 

Have INOL on the top of your screen tomorrow morning.

Situations like this do not come along every day. We urge members to take Swift Action and start your research right away. We could be looking at something Exceptional!

As always, we encourage you to do further research.

Technology is ever changing, but the quantum leap is in the making…..

TPTW has made two extremely important moves the past few months that, layered on top of the plans laid out in the latest Share Holder letter…. have a seat…. we are about to witness history.
 

TPT Global Tech Acquires the Patent Pending Full HD Naked Eye 3D Fully Functional Experience without 3D Glasses Mobility Technology

TPTW recently completed the purchase of the technology and intellectual property of Lion Universe Technologies www.lionuniverse.com, a Los Angeles-based Mobile Technology think tank. 

The Lion smartphone is the first Full HD Naked Eye 3D smartphone ever launched in the United States. Lion Universe mobile 3D technology is patent pending. 

The smartphone will be distributed through TPT Global Tech's wholly owned subsidiary K-TEL's existing brick and mortar distribution channel in the Northwest and very soon a National and International roll out.  TPTW is building industry leading personal cellular phones designed for a wide appeal. With a business model built on innovation and progress starting with the Lion Phone technology, the company produces high-quality and easy-to-use cellular phones.

The Lion Phone was designed for consumers looking for portable and affordable cutting-edge technology.  The Company's first-generation phones come equipped with full high definition resolution screen for better viewing. This Full HD Naked Eye 3D smartphone is perfect for watching movies, playing games, even editing photos or videos.

Performance and Portability

Whether it's looking at photos, playing music, emailing or surfing the web, consumers want more from their phones. The Lion Phone raises the bar for cellular phones. For the first time ever, cellular users can enjoy quality 3D viewing with the naked eye, no glasses required, enjoying full high definition video with smooth playback.

"Consumers have been waiting for a way to watch their favorite movies in 3D, now they can watch them in the convenience of their phone and Gamers can have the leisure of playing their games without taking all that head gear with them," said Enoch Brande, President of New Product Development, Lion Universe Technology. "Throughout our company, we strive to give customers the best possible experience with our Full HD Naked Eye 3D smartphone in the US and Global markets. "

TPTW added the patent pending Full HD Naked Eye 3D smartphone hardware technology to theirportfolios of companies. This acquisition continues their commitment in moving TPT Global Tech into the Global Mobile Digital Media Technology space.

9 Days later, the company begins to utilize the newly formed relationship with AT&T.
 

Trucom, an Arizona CLEC, launches wireless mobility products and services Nationwide operating on the AT&T 4G and 5G US Wireless Mobility Network

TPTW added the patent pending Full HD Naked Eye 3D smartphone hardware technology to theirportfolios of companies. This acquisition continues their commitment in moving TPT Global Tech into the Global Mobile Digital Media Technology space.

TPTW's Arizona based wholly owned subsidiary CLEC Trucom recently completed its AT&T Mobility wireless certification. Trucom is now positioned to launch Trucom Wireless and Broadband Services Nationally with its strategic partner AT&T, utilizing AT&T's mobility 4G and 5G National network. 

TruCom (www.trucom.com) is a Facilities Based Competitive Local Exchange Carrier (CLEC) headquartered in Phoenix, AZ.  Founded in 2006 for the purpose of operating a state-of-the-art Fiber Optic Network, Trucom operates its own carrier class Fiber Optic Network, state-of-the-art Wireless Point-to-Point network, and Patent Pending proprietary "Bulletproof^™" technology seamlessly integrating the two.

TruCom offers Phone, Internet, Fiber Optic, Wireless, Hosted PBX, Wi-Fi, Wi-Max, Engineering, Cabling, Wiring and Cloud services.  With a penchant for pushing the envelope, TruCom has pioneered innovative, hosted firewall and managed MPLS service technologies (SuperCore MPLS™) and was the Industry first to engineer patent-pending failover services utilizing our own fiber optic and wireless networks to guarantee business continuity and service uptime.  

Co-located in multiple Local Serving Offices and Points of Presence (POP's) in the primary Data Centers in the market, TruCom's extensive Fiber Optic Network runs through the heart of the most densely populated corridors of the Greater Phoenix Metro Area. Their Wireless Point to Point and Point to Multipoint Network is fed by the infinitely scalable capacity of the Fiber Optic Network and consists of more than 16 Major Access Points. 

"We here at TPT Global Tech are very pleased to add the patent pending Full HD Naked Eye 3D smartphone hardware technology to our portfolios of companies. This acquisition continues our commitment in moving TPT Global Tech into the Global Mobile Digital Media Technology space. We also look forward to continuing our working relationship with Linda Kelly who will continue to head Lion Phone division as its CEO and her outstanding tech team moving forward," said Stephen Thomas, CEO of TPT Global Tech Inc.

A few important points to keep in mind about TPTW:

• TPTW reported over $2Mill in Revs for 2016
• TPTW already showed over $700K in revs for Q1 of 2017
• TPTW is sporting a TINY FLOAT of only 4.4Mill shares

So, now that we have a very interesting picture of TPTW's future direction, and the fact that last time we discussed the chart and letter of share holders, we witnessed a 600% uptrend over the next thre days….this should be interesting.

Please start your research on TPTW right away and enjoy.

Disclaimer:
We have received five thousand dollars via a bank wire for the awareness of TPTW.

All of the information in this blog is gathered from public information released by the company.
By reading our newsletter you agree to the terms of our disclaimer, which are subject to change at any time. Owners and affiliates are not registered or licensed in any jurisdiction whatsoever to provide financial advice or anything of an advisory nature. Always do your own research and/or consult with an investment professional before investing. Low priced stocks are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service, you agree not to hold us, our editor's, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters, website, twitter, Facebook and chat. We do not advise any reader take any specific action. Our website, newsletter, twitter, Facebook and chat are for informational and educational purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter, twitter, Facebook and on our website, may be based on EOD or intraday data. We may be compensated for the production, release and awareness of this newsletter. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. Our emails may contain Forward Looking Statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters, twitter, Facebook our website and chat is believed to be accurate and correct, but has not been independently verified. The information in our disclaimers is subject to change at any time without notice.

We are not held liable or responsible for the information in press releases issued by the companies discussed in these email's. Please do your own due diligence.

This Undervalued Freight Transportation Company (listed below) is Making Some Big Changes, and It’s Poised to Surprise Investors in 2017

Despite what many believe, global trade is set to have some momentum in 2017 and one small NASDAQ company could be ready to take advantage of this shift in the marketplace. According to the World Trade Organization’s latest World Trade Outlook Indicator (WTOI), there may have been some continued momentum, from the fourth quarter of 2016, into the first quarter of 2017. This indicator provides data that include automobile sales, export orders, air freight, container shipping, electronic components and agricultural materials. Therefore, this tool is a prime indication of the trends of global trade.

Here’s a look at the recent WTOI reading, in late 2016:

Source: WTO

In addition to this above trend growth, as indicated above, the World Trade Organization (WTO) projected that world merchandise trade growth is set to grow between 1.8% and 3.1% in 2017. This forecasted growth rate could suggests increased volume, which could be beneficial for many companies.

With the potential growth in world trade, this translates to a potential growth in the shipping industry. However, some shipping companies are overvalued, and as you all may know, you generally want to buy low and sell high.

Now, more specifically, global trade growth should benefit the deep sea freight transportation industry. According to the St. Louis Federal Reserve Bank’s economic research, the producer price index in the deep sea freight transportation industry has been trending higher, as shown in the chart below.

Source: FRED

This means the deep sea freight transportation industry has been experiencing higher price levels, which could mean a potential increase in revenues, if the trend continues. Not only that, the Baltic Dry Index, which takes into account rates for ships carrying dry bulk commodities, recently hit over more than a two-year high, indicating there could be increasing demand for transporting major raw materials by sea.

Source: Bloomberg

The Baltic Dry Index has been trending higher, up as much as 50% at its highs in the past 12 months, providing an indication that deep sea transportation companies engaged in dry bulk shipping could potentially ride off the coattails of the potential increase in demand for these services.

With all the industry and world trend set to potentially grow in 2017, these developments have uncovered some interesting opportunities in some publicly-trade companies in the deep sea freight transportation industry. However, there’s one that stock that stands out, which could have an impressive upside potential. Let’s move onto an in-depth look at Seanergy Maritime Holdings Corp. (NASDAQ:SHIP).

Seanergy Maritime Holdings (NASDAQ:SHIP) is an international deep sea transportation shipping company primarily focused on providing marine drybulk transportation services. That in mind, SHIP owns and operates dry bulk vessels to do so. The company owns and operates a modern fleet of ten dry bulk carriers, which consists of eight Capesizes and two Supramaxes, and its fleet has a combined cargo-carrying capacity of over 1.5M dwt. The company recently acquired another Capesize fleet, which upon its delivery, would increase its modern fleet to 11 drybulk carriers. As we’ve already stated earlier, the potential increase in demand coupled with the projected growth rate of global trade means Seanergy is poised to grow its revenues and earnings, potentially translating to an increase in its stock price.

Seanergy’s Fleet is Strong

Source: Company’s Website

SHIP‘s current eleven vessel fleet is strategically placed in various parts of the world, such as Africa, South America, Asia and the middle east. With that in mind, these placements  are focused around some producers of major raw materials which means NASDAQ:SHIP is poised to take advantage of the demand for drybulk sea transportation. Among the company’s largest ships, recently acquired Capesize vessel to be renamed Partnership, which is expected to be delivered in June 2017. The Partnership has a capacity of 179K dwt. With the potential increase in demand for major raw materials and SHIP’s placement of its shipping vessels, its revenues could continue to rise.

According to SHIP Chief Executive Officer Stamatis Tsantanis, “We are very pleased to announce another acquisition of a modern Capesize vessel. This high quality Capesize vessel marks our first acquisition of 2017 and follows the successful acquisition and delivery of two sistership Capesizes in the fourth quarter of 2016. In addition, this purchase allows us to expand further our sizable position in the Capesize segment. We strongly believe that the Capesize segment represents the best fundamentals in the dry bulk industry and we will continue to actively pursue accretive acquisition opportunities of quality Capesize vessels with an aim of increasing value for our shareholders.”

Source: Company’s Website

This acquisition of a high-quality Capesize vessel allows the company to expand and bolster its position in the Capesize drybulk transportation segment. As the company increases its vessel size, it could take on more business from producers of major raw materials, translating into higher potential sales and profits. That said, if market participants catch wind of this, the market could price this in, potentially leading to a higher stock price. Thereafter, if its financial statements continue to show growth, SHIP could run higher.

Seanergy Could Increase its Equity, and Strengthen Balance Sheet

In March 2017, Seanergy announced it entered into a definitive agreement with one of its senior lenders in order to repay a credit facility, early. Consequently, SHIP expects this early repayment to result into a potential material gain and an increase in equity. Specifically, this gain is projected to be over $11M, representing around 29% of the outstanding facility. In turn, this transaction could drive SHIP‘s total equity up by over 30%, on an adjusted basis.

When speaking about this transaction Tsantanis said, “We are very pleased to announce another important transaction for the Company, which should result in significant accretion for our shareholders. Not only are we growing our fleet but we are streamlining our capital structure to be in a position to further capitalize on a strengthening dry bulk market. In the past six months Seanergy has successfully raised funds from the equity capital markets and used this capital for highly accretive and productive purposes to grow its platform and enhance shareholder value.”

Moreover, the CEO showed confidence in the company and believes the recent accretive acquisitions are consistent with its business strategy. Tsantanis also noted that the company is looking into additional transactions that are expected to enhance the value to shareholders and therefore the Company’s stock price.

The company looks like it could strengthen its balance sheet and income statement, potentially creating more value to SHIP stockholders.

Moving on, the company had some notable achievements during the 2016 fiscal year.

Seanergy Maritime Holdings 2016 Financial Highlights

Data Provided by Morningstar

If you look at the chart above, notice how Seanergy Maritime Holdings (NASDAQ:SHIP) has been consistently growing its revenue since the third quarter of the 2015 fiscal year. That in mind, the company grew its revenue from just over $2.6M in the third quarter over 2015, to over $8.6M in the third quarter of the 2016 fiscal year.

Seanergy continued its strong growth in its income statement during the fourth quarter of 2016. SHIP generated net revenue of $10.9M during the fourth quarter of 2016, and $34.7M for the full year. Additionally, what may be more attractive to investors was its growth in its total shareholders’ equity, which grew to $30.8M in 2016, up from $23.3M in 2015, or a growth rate of 32%. Not only that, but with the company’s acquisition of two modern Capesize vessels in 2016, and consequently, its increase its dwt capacity by 30%. In turn, this indicates SHIP has the ability to further grow its revenues in 2017. Additionally, with its recent early repayment of a credit facility, SHIP could grow its total shareholders’ equity even more in 2017.

SHIP Could Rise Soon

The potential rise in global trade and demand for major raw materials and deep sea freight transportation companies focused on drybulk shipping could move in tandem to those growth rates, which would allow companies like Seanergy Maritime Holdings (NASDAQ:SHIP) to generate higher revenues. Micro- and small-cap deep sea freight transportation stocks, such as SHIP, have large upside potential due to the these potential changes in the industry. SHIP had some developments that could potentially be indications that the company could grow its revenues and total stockholders’ equity. If Seanergy continues with its business strategy, and to increase shareholder value, this stock could start moving higher.

Sincerely,

Awesome Stock Tips

Disclaimer:

We have received ten thousand dollars for the awareness of SHIP.

Disclaimer:
Stockchat LLC has previously received 28,000 dollars for the awareness of THNS from a third party which has since expired.
Stockchat LLC has previously received 10,000 dollars for the awareness of SITO from a third party which has since expired.
Stockchat LLC has previously received 15,000 dollars for the awareness of OOIL from a third party which has since expired.
Stockchat LLC has previously received 41,000 dollars for the awareness of AXXE from a third party which has since expired.
Stockchat LLC has previously received 13,000 dollars for the awareness of STVF from a third party which has since expired.
Stockchat LLC has previously received 27,000 dollars for the awareness of NGMC from a third party which has since expired.
Stockchat LLC has previously received 8,000 dollars for the awareness of NPWZ from a third party which has since expired.
Stockchat LLC has previously received 4,000 dollars for the awareness of LIVE from a third party which has since expired.
Stockchat LLC has previously received 14,000 dollars for the awareness of DRMC from a third party which has since expired.
Stockchat LLC has previously received 15,000 dollars for the awareness of ETBI from a third party which has since expired.
Stockchat LLC has previously received 60,000 dollars for the awareness of DIGX from a third party which has since expired.
Stockchat LLC has previously received 15,000 dollars for the awareness of STHC from a third party which has since expired.
Stockchat LLC has previously received 7,000 dollars for the awareness of XDSL from a third party which has since expired.
Stockchat LLC has previously received 32,000 dollars for the awareness of CMXC from a third party which has since expired.
Stockchat LLC has previously received 90,000 dollars for the awareness of XTRM  from a third party which has since expired.
Stockchat LLC has previously received 40,000 dollars for the awareness of FLSR from a third party which has since expired.
Stockchat LLC has previously received 14,000 dollars for the awareness of VMRI from a third party which has since expired.
Stockchat LLC has previously received 23,000 dollars for the awareness of PSID from a third party which has since expired.
Stockchat LLC has previously received 40,000 dollars for the awareness of TPHX from a third party which has since expired.
Stockchat LLC has previously received 5,000 dollars for the awareness of PMCB from a third party which has since expired.
Stockchat LLC has previously received 47,000 dollars for the awareness of AXXE from a third party which has since expired.
Stockchat LLC has previously received 5,000 dollars for the awareness of SPYR from a third party which has since expired.
Stockchat LLC has previously received 48,000 dollars for the awareness of EWRC from a third party which has since expired.
Stockchat LLC has previously received 46,000 dollars for the awareness of TPHX from a third party which has since expired.
Stockchat LLC has previously received 6,000 dollars for the awareness of UMAX from a third party which has since expired.
Stockchat LLC has previously received 13,000 dollars for the awareness of TXHD from a third party which has since expired.
Stockchat LLC has previously received 6,000 dollars for the awareness of RLTR from a third party which has since expired.
Stockchat LLC has previously received 10,000 dollars for the awareness of VPLM from a third party which has since expired.
Stockchat LLC has previously received 10,000 dollars for the awareness of PFHS from a third party which has since expired.
Stockchat LLC has previously received 6,000 dollars for the awareness of FZRO from a third party which has since expired.
Stockchat LLC has previously received 7,000 dollars for the awareness of BWVI from a third party which has since expired.
Stockchat LLC has previously received 14,000 dollars for the awareness of AMFE from a third party which has since expired.
Stockchat LLC has previously received 6,000 dollars for the awareness of SIMH from a third party which has since expired.
Stockchat LLC has previously received 9,500 dollars for the awareness of VTMB from a third party which has since expired.
Stockchat LLC has previously received 16,000 dollars for the awareness of SBFM from a third party which has since expired.
Stockchat LLC has not been compensated in any way or form for the awareness of CYLC, INKN, FEWP, XPRT, PEFF, GNBA,
IYXI, AACS, AAGC, RCHA, SWMM, GMND, CWNR, NVNT, FLKI, HHWW, HOMS, BETS, LGBI, MGON, MCGI, BABL, WSRA,
LIBE, IGRW, GRCU, GOFF, INPH, FREE, DPW, DNRG, RXMD, CLRX, USMJ, CATV, SHIP, AXMM, FORD, TSOI, CALI, MLPH,
MCTC, KDKN, DYNV, ESYL, NSPR, LEI